Format
Sort by
Items per page

Send to

Choose Destination

Best matches for FILGRASTIM/PD:

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Dale DC et al. Support Care Cancer. (2018)

Conversion from Filgrastim to Tbo-filgrastim: Experience of a Large Health Care System. Agboola F et al. J Manag Care Spec Pharm. (2017)

Interchangeability of Biosimilars: A European Perspective. Kurki P et al. BioDrugs. (2017)

Search results

Items: 1 to 20 of 182

1.

Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel.

Nishimura M, Onoe T, Sakai H, Arase M, Watanabe S, Soyama M, Hashimoto K, Miki M, Tane K, Hirokaga K, Takao S, Matsumoto K.

Anticancer Res. 2019 Aug;39(8):4379-4383. doi: 10.21873/anticanres.13607.

PMID:
31366533
2.

[Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].

Kataoka T, Sakurashita H, Taogoshi T, Nishigakiuchi R, Murase T, Izumitani S, Saeki Y, Matsuo H.

Yakugaku Zasshi. 2019;139(4):629-633. doi: 10.1248/yakushi.18-00101. Japanese.

3.
4.

LA-EP2006: A Pegfilgrastim Biosimilar.

Hoy SM.

BioDrugs. 2019 Apr;33(2):229-232. doi: 10.1007/s40259-019-00348-3. Review.

PMID:
30887256
5.

Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies.

Harbeck N, Wang J, Otto GP, Gattu S, Krendyukov A.

Future Oncol. 2019 Apr;15(12):1313-1322. doi: 10.2217/fon-2018-0878. Epub 2019 Mar 5.

6.

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.

Ludwig H, Bokemeyer C, Aapro M, Boccadoro M, Gascón P, Denhaerynck K, Krendyukov A, Abraham I, MacDonald K.

Future Oncol. 2019 Mar;15(8):897-907. doi: 10.2217/fon-2018-0814. Epub 2019 Mar 4.

7.

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.

Waller CF, Ranganna GM, Pennella EJ, Blakeley C, Bronchud MH, Mattano LA Jr, Berzoy O, Voitko N, Shparyk Y, Lytvyn I, Rusyn A, Popov V, Láng I, Beckmann K, Sharma R, Baczkowski M, Kothekar M, Barve A.

Ann Hematol. 2019 May;98(5):1217-1224. doi: 10.1007/s00277-019-03639-5. Epub 2019 Mar 1.

8.

Monocytopenia in clozapine-induced agranulocytosis: insights into pathophysiology and treatment.

Patel R, Lima A, Burke C, Hoffman M.

BMJ Case Rep. 2019 Jan 18;12(1). pii: bcr-2018-226016. doi: 10.1136/bcr-2018-226016.

PMID:
30661042
9.

[A Case of Arteritis That Developed after Pegfilgrastim Administration during Chemotherapy for Breast Cancer].

Chino T, Oba T, Yamamoto K, Takekoshi D, Iesato A, Ito T, Kanai T, Maeno K, Ito K.

Gan To Kagaku Ryoho. 2018 Dec;45(12):1771-1774. Japanese.

PMID:
30587739
10.

Modification of the Myelotoxic and Antitumor Effects of Polychemotherapy by Polysaccharides from Tussilago farfara L.

Safonova EA, Lopatina KA, Razina TG, Zueva EP, Fedorova EP, Gur'ev AM, Belousov MV.

Bull Exp Biol Med. 2018 Dec;166(2):197-200. doi: 10.1007/s10517-018-4313-5. Epub 2018 Nov 28.

PMID:
30488221
11.

Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors.

Abboud CN, Lang N, Fung H, Lammerich A, Buchner A, Liu P, Mueller U, Pettengell R, Diel IJ, Link H, Pathak A.

Support Care Cancer. 2019 Jul;27(7):2569-2577. doi: 10.1007/s00520-018-4522-5. Epub 2018 Nov 15.

PMID:
30443809
12.

Application of G-CSF in Congestive Heart Failure Treatment.

Pourtaji A, Jahani V, Moallem SMH, Karimani A, Mohammadpour AH.

Curr Cardiol Rev. 2019;15(2):83-90. doi: 10.2174/1573403X14666181031115118. Review.

PMID:
30378501
13.

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).

Wolff T, Schulz H, Losem C, Reichert D, Hurtz HJ, Sandner R, Harde J, Grebhardt S, Potthoff K, Mueller U, Fietz T.

Eur J Haematol. 2019 Feb;102(2):174-181. doi: 10.1111/ejh.13189. Epub 2018 Nov 23.

PMID:
30347466
14.

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.

Ludwig H, Gascón P, Bokemeyer C, Aapro M, Boccadoro M, Denhaerynck K, Krendyukov A, MacDonald K, Abraham I.

Support Care Cancer. 2019 Jun;27(6):2301-2312. doi: 10.1007/s00520-018-4513-6. Epub 2018 Oct 20.

PMID:
30343410
15.

Severe thrombocytopenia related to filgrastim mobilization in a healthy donor.

Iltar U, Salim O, Küpesiz A.

Transfus Apher Sci. 2018 Dec;57(6):777-778. doi: 10.1016/j.transci.2018.10.002. Epub 2018 Oct 6. No abstract available.

PMID:
30340938
16.

The effect of pegylated granulocyte colony-stimulating factor on collateral function and myocardial ischaemia in chronic coronary artery disease: A randomized controlled trial.

Traupe T, Stoller M, Gloekler S, Meier P, Seiler C.

Eur J Clin Invest. 2019 Jan;49(1):e13035. doi: 10.1111/eci.13035. Epub 2018 Nov 6.

PMID:
30316200
17.

Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product.

Halim LA, Márquez M, Maas-Bakker RF, Castañeda-Hernández G, Jiskoot W, Schellekens H.

Pharm Res. 2018 Oct 2;35(11):226. doi: 10.1007/s11095-018-2491-5.

18.

First Pegfilgrastim Biosimilar Approved.

Aschenbrenner DS.

Am J Nurs. 2018 Oct;118(10):19-20. doi: 10.1097/01.NAJ.0000546389.75712.6e. No abstract available.

PMID:
30260881
19.

Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.

Yoshida Y, Komori K, Aoki M, Sandou M, Takagi M, Uejima E.

Pharmazie. 2018 Oct 1;73(10):613-616. doi: 10.1691/ph.2018.8576.

PMID:
30223928
20.

Influence of Modified Fucoidan and Related Sulfated Oligosaccharides on Hematopoiesis in Cyclophosphamide-Induced Mice.

Anisimova NY, Ustyuzhanina NE, Bilan MI, Donenko FV, Ushakova NA, Usov AI, Kiselevskiy MV, Nifantiev NE.

Mar Drugs. 2018 Sep 13;16(9). pii: E333. doi: 10.3390/md16090333.

Supplemental Content

Loading ...
Support Center